Comprehensive Introduction to IgG4 (Serum) Testing

The IgG4 (Serum) test is a specialized diagnostic assay used to quantify the concentration of immunoglobulin G subclass 4 in a patient's blood. While IgG is the most abundant immunoglobulin in human serum, comprising approximately 70-75% of total serum antibodies, it is further divided into four subclasses (IgG1, IgG2, IgG3, and IgG4). IgG4 is the least abundant subclass, typically representing less than 5% of total IgG.

Despite its low concentration in healthy individuals, IgG4 has gained significant clinical prominence over the last two decades due to its association with a distinct group of fibro-inflammatory conditions collectively known as IgG4-Related Disease (IgG4-RD). This guide provides an authoritative overview for clinicians and medical professionals regarding the diagnostic utility, interpretation, and clinical management associated with serum IgG4 levels.

Technical Specifications and Immunological Mechanisms

IgG4 is unique among the four IgG subclasses. Unlike IgG1, IgG2, and IgG3, IgG4 is unable to activate the classical complement pathway because it lacks the ability to bind C1q efficiently. Furthermore, IgG4 exhibits a phenomenon known as "Fab-arm exchange," where the antibody can swap half-molecules with other IgG4 molecules, resulting in bispecific antibodies that are functionally monovalent.

Mechanisms of Pathophysiology

In the context of IgG4-Related Disease, the pathophysiology involves:
* Chronic Inflammation: Sustained infiltration of lymphocytes and plasma cells into affected tissues.
* Fibrosis: Storiform (cartwheel-like) fibrosis is a hallmark histological finding.
* Obliterative Phlebitis: Inflammation involving the walls of small veins.
* Elevated Serum IgG4: While not present in all patients with the disease, significantly elevated serum levels are a key diagnostic marker.

Clinical Indications and Diagnostic Usage

The primary indication for ordering an IgG4 (Serum) test is the suspicion of IgG4-Related Disease. However, clinicians must be aware that elevated IgG4 is not pathognomonic for IgG4-RD, as it can be seen in other inflammatory and malignant conditions.

When to Order the Test:

1. Suspicion of IgG4-RD: Patients presenting with unexplained organ enlargement (e.g., pancreas, salivary glands, lacrimal glands, or retroperitoneum).
2. Differential Diagnosis of Pancreatitis: Distinguishing Autoimmune Pancreatitis (AIP) from adenocarcinoma.
3. Orbital Pseudotumor: Investigating unexplained orbital masses.
4. Retroperitoneal Fibrosis: Assessing for underlying systemic inflammatory processes.
5. Monitoring Treatment: Assessing the efficacy of immunosuppressive therapy (e.g., corticosteroids or rituximab) in patients previously diagnosed with IgG4-RD.

Clinical Utility Table

Reference Ranges and Interpretation

It is critical to note that reference ranges for IgG4 can vary significantly depending on the laboratory methodology (e.g., nephelometry vs. turbidimetry) and the demographic population.

Typical Reference Ranges

• Adults: 8 mg/dL – 140 mg/dL (0.08 – 1.40 g/L).
• Pediatrics: Reference ranges increase with age as the immune system matures.

Interpreting Elevated Levels

Elevated IgG4 (>140 mg/dL) does not automatically confirm a diagnosis of IgG4-RD. Clinicians must apply the "Rule of Three":
1. Clinical presentation: Does the patient have organ involvement consistent with IgG4-RD?
2. Serology: Is the IgG4 serum level elevated?
3. Histopathology: Does the biopsy show lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis?

Specimen Collection and Interfering Factors

To ensure accurate diagnostic results, specimen collection protocols must be strictly followed.

Specimen Requirements

• Specimen Type: Serum (SST or red-top tube).
• Volume: Minimum 1 mL of serum.
• Handling: Centrifuge and separate serum from cells within 2 hours of collection.
• Stability: Refrigerated (2-8°C) for up to 7 days; frozen (-20°C) for long-term storage.

Interfering Factors

• Lipemia: High triglyceride levels can interfere with optical measurements.
• Hemolysis: Severely hemolyzed samples may cause false results.
• Medication: Immunomodulatory drugs, specifically B-cell depleting therapies like Rituximab, will drastically reduce serum IgG4 levels regardless of disease activity.
• Laboratory Variation: Lack of international standardization for IgG4 assays can lead to inter-laboratory variability.

Risks, Side Effects, and Contraindications

As this is a blood-based laboratory test, there are no direct physiological risks to the patient other than standard phlebotomy-related issues:
* Bruising or hematoma at the puncture site.
* Vasovagal syncope (fainting) during blood draw.
* Minor bleeding (especially in patients on anticoagulants).

There are no absolute contraindications to performing an IgG4 serum test. However, clinicians should counsel patients that an abnormal result is a diagnostic tool, not a definitive diagnosis, and should not be interpreted in isolation.

Frequently Asked Questions (FAQ)

1. Is an elevated IgG4 level always indicative of IgG4-Related Disease?

No. Elevated IgG4 can occur in many conditions, including atopic diseases, certain infections, and malignancies. It is a supportive, not diagnostic, marker.

2. Can IgG4-RD occur with normal serum IgG4 levels?

Yes. Approximately 30-50% of patients with biopsy-proven IgG4-RD have normal serum IgG4 levels. A normal result does not rule out the disease.

3. What is the role of Rituximab in IgG4 testing?

Rituximab is a monoclonal antibody that depletes B-cells. Since plasma cells (which produce IgG4) are derived from B-cells, Rituximab treatment typically causes a rapid decline in serum IgG4, often masking the disease activity.

4. How often should IgG4 be monitored during treatment?

The frequency of testing depends on the clinical response. Typically, it is measured at baseline, 3 months, and 6 months to monitor for decreases in levels correlating with clinical improvement.

5. Does diet affect IgG4 levels?

There is no evidence that dietary intake significantly alters serum IgG4 levels in the short term.

6. Is IgG4-RD an autoimmune disease?

It is classified as an immune-mediated fibro-inflammatory condition. While it shares features with autoimmune diseases, its exact etiology remains under investigation.

7. What is "storiform fibrosis"?

This is a specific pattern of fibrosis seen under a microscope in tissue biopsies of IgG4-RD patients, characterized by a cartwheel-like arrangement of fibroblasts.

8. Are there age-related differences in IgG4 levels?

Yes, infants have very low levels of IgG4, which gradually increase through childhood as the immune system encounters environmental antigens.

9. Can other laboratory tests help confirm IgG4-RD?

Yes, clinicians often order total IgG, ANA (to rule out lupus), and inflammatory markers like CRP or ESR, though these are often normal in IgG4-RD.

10. Where can I find the most updated diagnostic criteria?

The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) published comprehensive classification criteria for IgG4-RD in 2019, which serve as the gold standard for clinical practice.

Conclusion

The measurement of serum IgG4 is an essential component in the diagnostic workup of patients presenting with mysterious inflammatory or fibrotic processes. By integrating serum IgG4 results with clinical presentation and histopathological data, physicians can accurately diagnose and manage IgG4-Related Disease. As our understanding of this condition evolves, standardized testing and rigorous interpretation remain the cornerstones of high-quality patient care in rheumatology, gastroenterology, and internal medicine.